Clinical prognostic factors in patients (pts) with recurrent and/or metastatic (RM) head and neck carcinoma (HNC) treated with cetuximab plus chemotherapy

被引：0
|
作者：
Bossi, P. [1 ]
Depenni, R. [2 ]
Rocca, M. Cossu [3 ]
Ferrari, D. [4 ]
Azzarello, G. [5 ]
Alu, M. [6 ]
Nole, F. [3 ]
Codeca, C. [4 ]
Boscolo, G. [5 ]
Piccininni, M. [7 ]
Cavalieri, S. [1 ]
Pugliese, G. [8 ]
Licitra, L. F. [1 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Head & Neck Med Oncol Unit, Milan, Italy
[2] Modena Canc Ctr, Dept Hematol Oncol, Modena, Italy
[3] Ist Europeo Oncol, Med Oncol, Milan, Italy
[4] Azienda Osped San Paolo, Oncol, Milan, Italy
[5] Unita Locale Socio Sanit 13, Dept Internal Med Sci, Oncol Unit, Mirano, Italy
[6] Arnas Civico, Med Oncol, Palermo, Italy
[7] Univ Bari Aldo Moro, Basic Med Sci Neurosci & Sense Organs, Bari, Italy
[8] Azienda Osped Univ Policlin Modena, Oncol, Modena, Italy
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1094P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy
    Magnes, Teresa
    Melchardt, Thomas
    Weiss, Lukas
    Mittermair, Christof
    Neureiter, Daniel
    Klieser, Eckhard
    Gampenrieder, Simon
    Moser, Gerhard
    Gaggl, Alexander
    Greil, Richard
    Egle, Alexander
    PLOS ONE, 2017, 12 (07):
  • [2] Activity of weekly paclitaxel−cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors
    I. Pajares Bernad
    J. Martínez Trufero
    L. Calera Urquizu
    R. A. Pazo Cid
    A. Cebollero de Miguel
    M. J. Agustin
    M. Lanzuela
    A. Antón
    Clinical and Translational Oncology, 2017, 19 : 769 - 776
  • [3] Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting
    Depenni, Roberta
    Rocca, Maria Cossu
    Ferrari, Daris
    Azzarello, Giuseppe
    Baldessari, Cinzia
    Alu, Massimiliano
    Nole, Franco
    Codeca, Carla
    Boscolo, Giorgia
    Piccininni, Marco
    Cavalieri, Stefano
    Bossi, Paolo
    EUROPEAN JOURNAL OF CANCER, 2019, 115 : 4 - 12
  • [4] Clinical prognostic factors in patients with recurrent or metastatic carcinoma of the head and neck treated with immune checkpoints therapies.
    Resteghini, Carlo
    Cavalieri, Stefano
    Rametta, Alessandro
    Alfieri, Salvatore
    Galbiati, Donata
    Platini, Francesca
    Locati, Laura Deborah
    Bossi, Paolo
    Bergamini, Cristiana
    Granata, Roberta
    Orlandi, Ester
    Piazza, Cesare
    Mancinelli, Moela
    Licitra, Lisa F.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Activity of weekly paclitaxel-cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors
    Pajares Bernad, I.
    Martinez Trufero, J.
    Calera Urquizu, L.
    Pazo Cid, R. A.
    Cebollero de Miguel, A.
    Agustin, M. J.
    Lanzuela, M.
    Anton, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (06): : 769 - 776
  • [6] Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab
    Pogorzelski, Michael
    Hilser, Thomas
    Ting, Saskia C.
    Kansy, Benjamin
    Gauler, Thomas C.
    Stuschke, Martin
    Schmid, Kurt W.
    Lang, Stephan
    Gruenwald, Viktor
    Schuler, Martin
    Kasper, Stefan
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [7] A real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: A prospective observation study (JROSG12-2)
    Yokota, T.
    Ota, Y.
    Fujii, H.
    Kodaira, T.
    Shimokawa, M.
    Nakashima, T.
    Monden, N.
    Homma, A.
    Ueda, S.
    Akimoto, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S678 - S679
  • [8] Real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: a prospective observation study (JROSG12-2)
    Yokota, Tomoya
    Ota, Yosuke
    Fujii, Hirofumi
    Kodaira, Takeshi
    Shimokawa, Mototsugu
    Nakashima, Torahiko
    Monden, Nobuya
    Homma, Akihiro
    Ueda, Shinya
    Akimoto, Tetsuo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (02) : 316 - 325
  • [9] Real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: a prospective observation study (JROSG12-2)
    Tomoya Yokota
    Yosuke Ota
    Hirofumi Fujii
    Takeshi Kodaira
    Mototsugu Shimokawa
    Torahiko Nakashima
    Nobuya Monden
    Akihiro Homma
    Shinya Ueda
    Tetsuo Akimoto
    International Journal of Clinical Oncology, 2021, 26 : 316 - 325
  • [10] Survival outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting
    Pontes, F.
    Rego, I.
    Domingues, I. C.
    Pinto, L.
    Garcia, R.
    Teixeira, M. M.
    Khoury, L.
    Serra, T.
    Mariano, M.
    Sousa, G. M.
    ANNALS OF ONCOLOGY, 2019, 30
12345